Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Industry Publications
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Search

P&MA Assessment to Support BD&L Decision-Making

Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making. Geographic Scope: Client Situation The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making. Trinity’s Solution Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for…

Read Now

Cross-Functional Launch Strategy Alignment Workshop

Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan. Geographic Scope: Client Situation: The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks. Trinity’s Solution: Trinity conducted targeted secondary research to determine the existing mNSCLC…

Read Now

Biosimilar Differentiation Strategy

Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries. Geographic Scope: Client Situation: The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars. Trinity’s Solution Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185…

Read Now

Strategic Recommendations About Potential Actions to Shape Bone Health Policy

Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets. Geographic Scope: Client Situation The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy. Trinity’s Solution Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space. Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…

Read Now

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

July 14, 2020 Executive Summary Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptakePayers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritizationPharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely…

Read Now

Commercial VP/SVP Pipeline Development for Women in Life Sciences

A life science company engaged TGaS Advisors to: Investigate drivers for gender diversity in VP/SVP commercial rolesBenchmark high-performing companies (in/ex industry) with above-average numbersof women in executive rolesBenchmark the key competencies and skills of women in executive commercial roles Complete the form below to view the brief…

Read Now

2019 NRDL: Insights for Future Pricing Negotiations in China

June 2, 2020 Executive Summary China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers…

Read Now

COVID-19 Briefing Series: Launch in the Age of COVID-19

While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace. How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world? Publication Access Form…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.